Introduction: The aim of this multicenter study was to investigate the prognostic impact of residual T1 high-grade (HG)/G3 tumors at re-transurethral resection (TUR of bladder tumor) in a large multi-institutional cohort of patients with primary T1 HG/G3 bladder cancer (BC). Patients and Methods: The study period was from January 2002 to -December 2012. A total of 1,046 patients with primary T1 HG/G3 and who had non-muscle invasive BC (NMIBC) on re-TUR followed by adjuvant intravesical Bacillus Calmette-Guerin (BCG) therapy with maintenance were included. Endpoints were time to disease recurrence, progression, and overall and cancer-specific death. Results: A total of 257 (24.6%) patients had residual T1 HG/G3 tumors. The presence of concomitant carcinoma in situ, multiple and large tumors (> 3 cm) at first TUR were associated with residual T1 HG/G3. Five-year recurrence-free survival (RFS), progression-free survival (PFS), overall survival (OS), and cancer-specific survival (CSS) were 17% (CI 11.8–23); 58.2% (CI 50.7–65); 73.7% (CI 66.3–79.7); and 84.5% (CI 77.8–89.3), respectively, in patients with residual T1 HG/G3, compared to 36.7% (CI 32.8–40.6); 71.4% (CI 67.3–75.2); 89.8% (CI 86.6–92.3); and 95.7% (CI 93.4–97.3), respectively, in patients with NMIBC other than T1 HG/G3 or T0 tumors. Residual T1 HG/G3 was independently associated with RFS, PFS, OS, and CSS in multivariable analyses. Conclusions: Residual T1 HG/G3 tumor at re-TUR confers worse prognosis in patients with primary T1 HG/G3 treated with maintenance BCG. Patients with residual T1 HG/G3 for primary T1 HG/G3 are very likely to fail BCG therapy alone.

Keywords:
High-grade, Bladder cancer, High risk, Transurethral resection of bladder tumor, Second look resection
1.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87–108.
2.
Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, et al: ICUD-EAU international consultation on bladder cancer 2012: screening, diagnosis, and molecular markers. Eur Urol 2013; 63: 4–15.
3.
Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, et al: EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017; 71: 447–461.
4.
Martin-Doyle W, Leow JJ, Orsola A, Chang SL, Bellmunt J: Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients. J Clin Oncol 2015; 33: 643–650.
5.
Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al: Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO Guideline. J Urol 2016; 196: 1021–1029.
6.
Poletajew S, Zapała P, Radziszewski P: Safety and efficacy of intravesical bacillus calmette-guérin immunotherapy in patients with non-muscle-invasive bladder cancer presenting with asymptomatic bacteriuria: a systematic review. Urol Int 2017; 99: 1–5.
7.
Steinberg RL, Thomas LJ, O’Donnell MA: Bacillus calmette-guérin (BCG) treatment failures in non-muscle invasive bladder cancer: what truly constitutes unresponsive disease. Bladder Cancer 2015; 1: 105–116.
8.
Daneshmand S: Determining the role of cystectomy for high-grade T1 urothelial carcinoma. Urol Clin North Am 2013; 40: 233–247.
9.
Badalato GM, Gaya JM, Hruby G, Patel T, Kates M, Sadeghi N, et al: Immediate radical cystectomy vs conservative management for high grade cT1 bladder cancer: is there a survival difference? BJU Int 2012; 110: 1471–1477.
10.
Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y: Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 2007; 109: 1106–1113.
11.
Byrne RR, Shariat SF, Brown R, Kattan MW, Morton RA JR, Wheeler TM, et al: E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol 2001; 165: 1473–1479.
12.
Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, et al: Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol 2010; 57: 300–309.
13.
Breyer J, Otto W, Wirtz RM, Wullich B, Keck B, Erben P, et al: ERBB2 expression as potential risk-stratification for early cystectomy in patients with pT1 bladder cancer and concomitant carcinoma in situ. Urol Int 2017; 98: 282–289.
14.
Woldu SL, Bagrodia A, Lotan Y: Guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int 2017; 119: 371–380.
15.
Gontero P, Sylvester R, Pisano F, Joniau S, Oderda M, Serretta V, et al: The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin. BJU Int 2016; 118: 44–52.
16.
Herr HW, Donat SM: A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int 2006; 97: 1194–1198.
17.
Divrik RT, Sahin AF, Yildirim U, Altok M, Zorlu F: Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol 2010; 58: 185–190.
18.
Del Zingaro M, Bruno R, Nunzi E, Porena M, Mearini L: First and second transurethral resections in intermediate-high risk bladder cancer: impact of the surgeon's volume on the recurrence and progression of primary bladder cancer. Minerva Urol Nefrol 2016; 68: 194–203.
19.
Balan D, Martha O, Chibelean CB, Tataru S, Voidezan S, Sin A, et al.: Comparison of 10-year overall survival between patients with G1 and G2 grade Ta bladder tumors. Medicine (Baltimore) 2018; 97:e0522.
20.
Hofbauer SL, Shariat SF, Chade DC, Sarkis AS, Ribeiro-Filho LA, Nahas WC, et al: The moreau strain of Bacillus Calmette-Guerin (BCG) for high-risk non-muscle invasive bladder cancer: an alternative during worldwide BCG shortage? Urol Int 2016; 96: 46–50.
21.
Lamm DL: Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer. Clin Infect Dis 2000; 31(suppl 3):S86–S90.
22.
Rink M, Fajkovic H, Cha EK, Gupta A, Karakiewicz PI, Chun FK, et al: Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol 2012; 61: 854–855.
23.
Vasdev N, Dominguez-Escrig J, Paez E, Johnson MI, Durkan GC, Thorpe AC: The impact of early re-resection in patients with pT1 high-grade non-muscle invasive bladder cancer. Ecancermedicalscience 2012; 6: 269.
24.
Audenet F, Retinger C, Chien C, Benfante NE, Bochner BH, Donat SM, et al: Is restaging transurethral resection necessary in patients with non-muscle invasive bladder cancer and limited lamina propria invasion? Urol Oncol 2017; 35: 603.e1–e603.e5.
25.
Takaoka E, Matsui Y, Inoue T, Miyazaki J, Nakashima M, Kimura T, et al: Risk factors for intravesical recurrence in patients with high-grade T1 bladder cancer in the second TUR era. Jpn J Clin Oncol 2013; 43: 404–409.
26.
Gill TS, Das RK, Basu S, Dey RK, Mitra S: Predictive factors for residual tumor and tumor upstaging on relook transurethral resection of bladder tumor in non-muscle invasive bladder cancer. Urol Ann 2014; 6: 305–308.
27.
Kamiya N, Suzuki H, Suyama T, Kobayashi M, Fukasawa S, Sekita N, et al: Clinical outcomes of second transurethral resection in non-muscle invasive high-grade bladder cancer: a retrospective, multi-institutional, collaborative study. Int J Clin Oncol 2017; 22: 353–358.
28.
Turk H, Un S, Isoglu CS, Karabicak M, Ergani B, Yoldas M, et al: Factors that predict residual tumors in re-TUR patients. Afr J Urol 2016; 22: 67–70.
29.
Holmang S: High-grade non-muscle-invasive bladder cancer: Is re-resection necessary in all patients before intravesical bacillus Calmette-Guerin treatment? Scand J Urol 2013; 47: 363–369.
30.
Bishr M, Lattouf JB, Latour M, Saad F: Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer. Can Urol Assoc J 2014; 8:E306–E310.
31.
Hemdan T, Johansson R, Jahnson S, Hellstrom P, Tasdemir I, Malmstrom PU: 5-year outcome of a randomized study comparing bacillus Calmette-Guerin with epirubicin and interferon-α2b in patients with T1 bladder cancer. J Urol 2014; 191: 1244–1249.
32.
Sanseverino R, Napodano G, Campitelli A, Addesso M: Prognostic impact of ReTURB in high grade T1 primary bladder cancer. Arch Ital Urol Androl 2016; 88: 81–85.
33.
Tae BS, Jeong CW, Kwak C, Kim HH, Moon KC, Ku JH: Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer. PLoS One 2017; 12: e0189354.
34.
Breau RH, Karnes RJ, Farmer SA, Thapa P, Cagiannos I, Morash C, et al: Progression to detrusor muscle invasion during urothelial carcinoma surveillance is associated with poor prognosis. BJU Int 2014; 113: 900–906.
35.
Vartolomei MD, Kiss B, Vidal A, Burkhard F, Thalmann GN, Roth B: Long-term results of a prospective randomized trial assessing the impact of re-adaptation of the dorsolateral peritoneal layer after extended pelvic lymph node dissection and cystectomy. BJU Int 2016; 117: 618–628.
36.
Gupta A, Lotan Y, Bastian PJ, Palapattu GS, Karakiewicz PI, Raj GV, et al: Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. Urology 2008; 71: 302–307.
37.
Karakiewicz PI, Shariat SF, Palapattu GS, Perrotte P, Lotan Y, Rogers CG, et al: Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol 2006; 50: 1254–1260;discussion 1261–1262.
38.
Martha O, Porav-Hodade D, Bălan D, Tătaru OS, Sin A, Chibelean CB, et al: Easily available blood test neutrophil-to-lymphocyte ratio predicts progression in high-risk non-muscle invasive bladder cancer. Rev Romana Med Lab 2017; 25: 181–189.
39.
Mbeutcha A, Shariat SF, Rieken M, Rink M, Xylinas E, Seitz C, et al: Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer. Urol Oncol 2016; 34: 483.e17–e483.e24.
40.
Shariat SF, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U, et al: International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int 2010; 105: 1402–1412.
41.
Moschini M, D’Andrea D, Korn S, Irmak Y, Soria F, Compérat E, et al: Characteristics and clinical significance of histological variants of bladder cancer. Nat Rev Urol 2017; 14: 651–668.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.